RxDoctor Payments DataLook up a doctor →

Yadagiri Chepuru, MD

Psychiatry · Yonkers, NYNPI 1700929809

Payments from drug & device makers

$962,599in general payments, 2019–2025

Across 1,158 payments — averaging $831.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$301K
  • Teva Pharmaceuticals USA, Inc.$237K
  • Otsuka America Pharmaceutical, Inc.$123K
  • Acadia Pharmaceuticals Inc$87K
  • E.r. Squibb & Sons, L.L.C.$75K
  • Axsome Therapeutics, Inc.$61K
  • plus $78K from 12 others

What the payments were for

  • Consulting fees$104,94911%
  • Speaking & faculty fees$757,20579%
  • Travel & lodging$69,1767%
  • Food & beverage$30,7823%
  • Education$4870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$962,599 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$8,275
Medicare patients
51
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine12$96,948
NuedextaDextromethorphan Hbr/Quinidine23$37,413
VraylarCariprazine Hcl12$33,245
TrintellixVortioxetine Hydrobromide25$16,215
Asenapine Maleate11$2,586
Risperidone OdtRisperidone13$2,345
Clozapine43$1,130
Lurasidone Hcl12$1,069
Divalproex Sodium ErDivalproex Sodium24$959
Haloperidol24$807
Quetiapine Fumarate ErQuetiapine Fumarate15$796
Alprazolam59$709
Gabapentin12$663
Benztropine Mesylate37$473
Clonazepam45$468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$237,214$96,94812 claims
Avanir Pharmaceuticals, Inc.Nuedexta$43$37,41323 claims
AbbVieVraylar$25,424$33,24512 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$8,393$16,21525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Yonkers

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →